GleamWall
中文EN

BIVI BIOVIE INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1580149 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-22.3%
TTM EPS YoY54.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-143.7%
ROA-119.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets40.9%
Debt / equity0.00x
Current ratio2.40x
Interest coverage-1,363.57x

Cash quality & payout

Operating cash flow / net income0.84x
Accruals ratio-19.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue————————
R&D expense$3.34M$3.58M$3.18M$4.27M$2.94M$1.22M$1.34M$4.70M
SG&A expense$2.31M$2.13M$2.15M$1.94M$2.29M$2.38M$1.59M$2.53M
Operating income-$5.65M-$5.72M-$5.39M-$6.26M-$5.28M-$3.66M-$2.99M-$7.29M
Interest expense$968$3,978$5,967$5,967$1,989$4,998$4,998$66,700
Net income-$5.61M-$5.65M-$5.27M-$6.07M-$5.09M-$3.49M-$2.79M-$7.11M
EPS (basic)-0.68—-0.70-0.77-0.98—-1.51-4.55
EPS (diluted)-0.68—-0.70-0.77-0.98—-1.51-4.55
Weighted avg. shares (diluted)8.27M—7.54M7.92M5.21M—1.85M1.57M
Balance sheet
Cash & equivalents$7.73M$8.98M$13.10M$20.54M$24.98M$17.54M$23.15M$24.41M
Current assets$10.45M$13.64M$16.88M$21.79M$26.03M$20.70M$23.72M$24.68M
Goodwill$345,711$345,711$345,711$345,711$345,711$345,711$345,711$345,711
Intangibles——$6,308$63,653$120,997$178,341$235,685$293,030
Total assets$11.04M$14.25M$17.51M$22.50M$26.82M$21.56M$24.66M$25.69M
Current liabilities$4.35M$3.80M$1.69M$3.01M$1.64M$2.27M$2.55M$1.46M
Total liabilities$4.51M$3.98M$1.91M$3.24M$1.90M$2.55M$2.84M$1.77M
Shareholders' equity$6.53M$10.27M$15.61M$19.27M$24.92M$19.01M$21.82M$23.92M
Shares outstanding8.69M7.54M7.54M7.54M7.54M1.91M18.52M18.45M
Cash flow statement
Operating cash flow-$2.91M-$4.12M-$7.44M-$4.44M-$3.02M-$5.61M-$1.25M-$8.58M
Financing cash flow$1.66M$0$0$0$10.46M$0$0$12.97M
Stock-based compensation$202,544$256,719$1.56M$197,336$268,388$352,809$338,412$385,328

Free plan shows the latest 8 periods; Pro shows all 54 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.